| __timestamp | Lantheus Holdings, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 72429000 | 612613000000 |
| Thursday, January 1, 2015 | 78634000 | 650773000000 |
| Friday, January 1, 2016 | 75374000 | 619061000000 |
| Sunday, January 1, 2017 | 92157000 | 628106000000 |
| Monday, January 1, 2018 | 93326000 | 717599000000 |
| Tuesday, January 1, 2019 | 103132000 | 964737000000 |
| Wednesday, January 1, 2020 | 110171000 | 875663000000 |
| Friday, January 1, 2021 | 218817000 | 886361000000 |
| Saturday, January 1, 2022 | 233827000 | 997309000000 |
| Sunday, January 1, 2023 | 267194000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Takeda Pharmaceutical Company Limited and Lantheus Holdings, Inc. from 2014 to 2023. Over this period, Takeda's SG&A expenses have shown a steady increase, peaking at approximately 1.05 trillion yen in 2023, marking a 72% rise from 2014. In contrast, Lantheus Holdings experienced a more dramatic growth, with expenses surging by 269% to reach 267 million dollars in 2023. This stark difference highlights Takeda's consistent yet moderate growth, while Lantheus's expenses reflect a more aggressive expansion strategy. Notably, data for Lantheus in 2024 is unavailable, indicating potential reporting delays or strategic shifts. This financial insight underscores the diverse strategies employed by these pharmaceutical giants in managing operational costs.
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited Trends and Insights
Regeneron Pharmaceuticals, Inc. vs Lantheus Holdings, Inc.: SG&A Expense Trends
Gross Profit Trends Compared: Takeda Pharmaceutical Company Limited vs Lantheus Holdings, Inc.
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs CymaBay Therapeutics, Inc.
Takeda Pharmaceutical Company Limited and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Mesoblast Limited Trends and Insights
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Lantheus Holdings, Inc.
Lantheus Holdings, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Merus N.V.
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Galapagos NV